In a study of female BRCA carriers, including ICARE participants, those that used tamoxifen and/or raloxifene
were compared to those that did not. After an average follow-up time of almost 7 years, 10.9% of those in the tamoxifen/raloxifene group were diagnosed with breast cancer, compared to 14.3% in the group that did not use these
drugs. This study suggests that chemoprevention through use of tamoxifen and/or raloxifene may work to reduce risks for
breast cancer in BRCA carriers, but more studies with longer follow-up are necessary.
Kotsopoulos, et al. Breast Cancer Res Treat. 2023;201(2):257-264. PMID: 37432545